HIMS vs. TDOC, AUNA, LFMD, AIRS, SHLT, PTWO, TOI, CANOQ, CCM, and ILMN
Should you be buying Hims & Hers Health stock or one of its competitors? The main competitors of Hims & Hers Health include Teladoc Health (TDOC), Auna (AUNA), LifeMD (LFMD), AirSculpt Technologies (AIRS), SHL Telemedicine (SHLT), Pono Capital Two (PTWO), Oncology Institute (TOI), Cano Health (CANOQ), Concord Medical Services (CCM), and Illumina (ILMN).
Teladoc Health (NYSE:TDOC) and Hims & Hers Health (NYSE:HIMS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, community ranking, analyst recommendations, risk and earnings.
Hims & Hers Health has a net margin of -0.24% compared to Hims & Hers Health's net margin of -8.90%. Teladoc Health's return on equity of -0.70% beat Hims & Hers Health's return on equity.
Teladoc Health received 642 more outperform votes than Hims & Hers Health when rated by MarketBeat users. Likewise, 63.35% of users gave Teladoc Health an outperform vote while only 33.75% of users gave Hims & Hers Health an outperform vote.
76.8% of Teladoc Health shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 1.0% of Teladoc Health shares are held by company insiders. Comparatively, 17.7% of Hims & Hers Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Hims & Hers Health has lower revenue, but higher earnings than Teladoc Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than Teladoc Health, indicating that it is currently the more affordable of the two stocks.
In the previous week, Hims & Hers Health had 4 more articles in the media than Teladoc Health. MarketBeat recorded 18 mentions for Hims & Hers Health and 14 mentions for Teladoc Health. Teladoc Health's average media sentiment score of 0.53 beat Hims & Hers Health's score of 0.25 indicating that Hims & Hers Health is being referred to more favorably in the news media.
Teladoc Health currently has a consensus price target of $18.22, suggesting a potential upside of 62.09%. Hims & Hers Health has a consensus price target of $15.69, suggesting a potential downside of 19.20%. Given Hims & Hers Health's higher possible upside, equities research analysts clearly believe Teladoc Health is more favorable than Hims & Hers Health.
Teladoc Health has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.
Summary
Hims & Hers Health beats Teladoc Health on 11 of the 17 factors compared between the two stocks.
Get Hims & Hers Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for HIMS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HIMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hims & Hers Health Competitors List
Related Companies and Tools
